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Abstract
Aims/hypothesis Extracellular matrix reorganisation is a
crucial step of adipocyte differentiation and is controlled
by the matrix metalloproteinase–tissue inhibitor of matrix
metalloproteinase (TIMP) enzyme system. We therefore
sought to define the role of TIMP1 in adipogenesis and to
elucidate whether upregulation of TIMP1 in obesity has
direct effects on adipocyte formation.
Methods TIMP1 protein levels and mRNA were measured
in lean and obese mice with a focus on levels in adipose
tissue. We also analysed the effect of recombinant murine
TIMP1 on adipogenesis, adipocyte size and metabolic
control in vitro and in vivo.
Results TIMP1 levels were increased in the serum and
adipose tissue of obese mouse models. Recombinant
murine TIMP1 inhibited adipocyte differentiation in 3T3-
L1 as well as in subcutaneous primary pre-adipocytes.
Conversely, neutralising TIMP1 with a specific antibody
enhanced adipocyte differentiation. In vivo, injection of
recombinant TIMP1 in mice challenged with a high-fat diet
led to enlarged adipocytes. TIMP1-treated mice developed
an impaired metabolic profile with increased circulating
NEFA levels, hepatic triacylglycerol accumulation and
accelerated insulin resistance. Altered glucose clearance in
TIMP1-injected mice was due to changes in adipose tissue
glucose uptake, whereas muscle glucose clearance
remained unaffected.
Conclusions/interpretation TIMP1 is a negative regulator
of adipogenesis. In vivo, TIMP1 leads to enlarged
adipocytes in the state of overnutrition. This might
contribute to the detrimental metabolic consequences seen
in TIMP1-injected mice, such as systemic fatty acid
overload, hepatic lipid accumulation and insulin resistance.
Keywords Adipocyte hypertrophy . Adipogenesis .
Diet-induced obesity . Insulin resistance . TIMP1 .
Tissue inhibitor of metalloproteinase 1
Abbreviations
MMP Matrix metalloproteinase
SVF Stromal–vascular fraction of adipose tissue
TIMP Tissue inhibitor of matrix metalloproteinase
Introduction
Obesity is the main risk factor for type 2 diabetes and
has become a growing health problem in the last
decades [1–3]. Expansion of adipose tissue results from
an imbalance between energy intake and energy expendi-
ture. Secondary complications caused by obesity partly
depend on how well adipose tissue can adapt to an
extended nutrient supply [4, 5]. One way of buffering
excess nutrients in adipose tissue is the generation of fat
cells through de novo differentiation. This hyperplastic
response is preferable to a hypertrophic reaction, where
nutrients are stored in pre-existing adipocytes. Adipocyte
hypertrophy commonly leads to enlarged, insulin-resistant
fat cells with a high lipolytic rate, thus promoting ectopic
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lipid accumulation and systemic insulin resistance [6–9].
New adipocytes can differentiate from precursor cells,
which reside in the stromal–vascular fraction of adipose
tissue (SVF) [10, 11]. For a fibroblast-like pre-adipocyte
to become a lipid-laden adipocyte, restructuring of the
extracellular matrix is indispensable [12–15]. Therefore,
extracellular matrix remodelling has an important impact
on adipocyte differentiation [16, 17]. The concomitant
extracellular protein degradation is mediated by matrix
metalloproteinases (MMPs) and their regulatory counter-
parts, the tissue inhibitors of matrix metalloproteinases
(TIMPs) [17].
Altered levels of MMPs have been observed in
adipose tissue of obese participants and the MMP
system is tightly regulated during adipogenesis [18].
MMPs influence the process of adipogenesis in a
repressive or activating way depending on substrate
specificity [17]. Mice deficient in MMP3, MMP11 or
MMP19 exhibit increased adiposity during diet-induced
obesity [19–21]. In female mice after lactation MMPs also
influence adipogenesis in the mammary gland. Loss of
MMP3, for example, leads to increased fat accumulation
[22]. Moreover, lack of plasminogen, a precursor of
plasmin, a key enzyme activating MMPs, blocks adipocyte
differentiation [23]. Finally, mice treated with a global
MMP inhibitor display reduced adipose tissue weight
concomitant with a lower total number of adipocytes when
exposed to a high-fat diet [24]. This is consistent with the
fact that the global MMP inhibitor BB-94 inhibits 3T3-L1
adipocyte differentiation [18].
MMPs are inhibited in 1:1 stoichiometry by the family
of TIMP proteins. TIMP1 inhibits most MMPs except
MMP14, MMP16 and MMP19 [25]. Analysis in adipose
tissue of lean and obese mice, and humans revealed
significant upregulation of TIMP1 in obesity [18, 26].
Conflicting data have been reported concerning the func-
tional role of TIMP1 in adipose tissue. Whereas male
TIMP1-deficient mice kept on a high-fat diet develop less
adiposity, female TIMP1-deficient mice accumulate more
adipose tissue due to hyperphagia [27, 28]. On the other
hand, systemic adenoviral overproduction of the human
TIMP1 homologue in mice had no effect on adipose tissue
mass [29]. In vitro, human TIMP1 did not influence
adipogenesis of murine 3T3-F442A cells, whereas in
another study, human TIMP1 accelerated 3T3-L1 differen-
tiation [22, 29]. A certain drawback here is the use of
human TIMP1 in mouse model systems, which might
disturb the interaction between MMPs and their inhibitors
due cross species differences.
As TIMP1 levels are upregulated in obesity, the aim of
this study was to define the role of TIMP1 in adipocyte
formation and its potential influence on metabolism in the
state of obesity.
Methods
Real-time PCR cDNA was produced using a cDNA kit
(Multi-MACS; Miltenyi, Bergisch Gladbach, Germany).
mRNA expression was assessed using SybrGreen (Invitrogen,
Basel, Switzerland) and normalised to Rplp0.
Primers (annealing temperature 60°C): Rplp0 forward
GCCGTGATGCCCAGGGAAGACA, Rplp0 reverse
CATCTGCTT GGAGCCCACGTTG; Timp1 forward
GATATGCCCACAAGTCCCAGAACC, Timp1 reverse
GCACACCCCACAGCCAGCACTAT; Pparγ (also known
as Pparg) forward AGGCGAGGGCGATCTTGACAG,
Pparγ reverse AATTCGGATGGCCACCTCTTTG; A-Fabp
(also known as Fabp4) forward ATGAAATCACCGCA
GACGACAG, A-Fabp reverse GCCTTTCATAAC
ACATTCCACCAC.
TIMP1 secretion from SVF SVF and adipocytes were
essentially isolated as described previously [30]. Adipose
tissue was digested for 1 h with 2 mg/ml collagenase
type II. Adipocytes were cultured in 24-well 0.4 μm
filter inserts (Becton Dickinson, Franklin Lakes, NJ,
USA). SVF was filtered through a 40 μm net and
erythrocytes were lysed. Cells were seeded on collagen-
coated plates at 80% density in high-glucose DMEM
with 10% (vol./vol.) fetal bovine serum and penicillin/
streptomycin. The next day, the medium was changed to
Krebs–Ringer buffer and collected after 24 h. TIMP1 in
the supernatant fraction was measured using an ELISA
kit (Quantikine Mouse TIMP1; R&D Systems, Minne-
apolis, MN, USA).
MMP activity assays Inhibition of MMP9 (Anaspec,
Fremont, CA, USA) by TIMP1 was tested using a kit
(SensoLyte 570 Generic MMP Assay Fluorimetric; Anas-
pec, Fremont, CA, USA). Human or murine MMP9 was
used at 30 ng/ml corresponding to enzyme:substrate ratios
of 1:43 to 1:350. Human TIMP1 was purchased from R&D
Systems (R&D Systems).
For global MMP activity from adipose tissue extracts,
frozen adipose tissue was dounced in 300 μl hypotonic buffer
(10 mmol/l KCl, 1.5 mmol/l MgCl2, 10 mmol/l HEPES
pH 7.9), and 375 μl hypertonic buffer (20 mmol/l HEPES/
KOH pH 7.9, 25% (vol./vol.) glycerol, 0.2 mmol/l EDTA,
1.5 mmol/l MgCl2, 1.2 mol/l NaCl) was added, followed by
incubation at 4°C for 30 min. Cleared lysates (50 μl) were
tested for MMP activity using the SensoLyte kit (Anaspec,
Fremont, CA, USA).
Recombinant murine Timp1 Murine Timp1 was cloned
from adipose tissue cDNA and ligated into the pSecTagA
vector (Invitrogen, Basel, Switzerland) using the following
primers: murine Timp1 forward AAGCTTTTGTAG
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CTGTGCCCCACCCCA, reverse CTCGAGTCGGGC
CCCAAGGGATCTCC. For protein production HEK293T
cells were transfected with lipofectamine (Invitrogen,
Basel, Switzerland). Opti-MEM supernatant fraction
was collected every 2 days. Murine TIMP1 was purified
twice via the his-tag using a Ni-NTA column (GE
Healthcare, Glattbrugg, Switzerland) connected to an
automated fast protein liquid chromatography system.
Murine TIMP1 was dialysed against PBS and analysed
by western blot using anti-his tag antibody (Cell
Signaling, Danvers, MA, USA) or Coomassie-stained
12% (wt/vol.) SDS-polyacrylamide gel.
Adipocyte differentiation 3T3-L1 pre-adipocytes and pri-
mary cells from SVF were cultured on collagen-coated
black 96-well plates in DMEM supplemented with 10%
(vol./vol.) fetal bovine serum and penicillin/streptomy-
cin. Adipogenesis was induced by treating 48 h post-
confluent 3T3-L1 pre-adipocytes or 80% confluent
stromal–vascular cells with induction medium (1 μg/ml
insulin, 1 μmol/l dexamethasone, 115 μg/ml isobutyl-
methylxanthine) for 2 days, followed by 2 days of
insulin medium (1 μg/ml) and 2 days of normal
medium. Murine TIMP1 at indicated concentrations,
monoclonal rat anti-mouse TIMP1 antibody (R&D
Systems) or rat IgG1 isotype control antibody (MBL,
Woburn, MA, USA) at 0.5 μg/ml were added to the
medium 24 h after cell seeding until the third day of
differentiation. Differentiated cells were fixed with 5%
(wt/vol.) formaldehyde and stained with 4 μmol/l Hoechst
(nuclei), 5 μmol/l Syto60 (cytosol) and 2 μmol/l Bodipy (lipid
droplets) or Oil Red O.We took nine pictures per well with an
automated microscope (CellWorx, Thermo Fisher Scientific,
Pittsburgh, PA, USA). Pictures were analysed using Cell
Profiler Software [31].
Adipose tissue western blots Adipose tissue extracts were
prepared as described under MMP activity assays. Protein
concentration was determined using the DC protein assay
(BioRad, Reinach, Switzerland). Tissue lysates were sub-
jected to 12% (wt/vol.) SDS-polyacrylamide gel electropho-
resis and western blotting using the following antibodies: goat
anti-mouse/rat MMP2 (1:1,000), goat anti-mouse MMP9
(1:1,000; R&D Systems), mouse anti-mouse γ-tubulin
(1:5,000; Sigma-Aldrich, Buchs, Switzerland).
TIMP1 levels in human obese participants TIMP1 serum
levels were measured in 20 obese men (BMI 32.9–54.9 kg/m2)
using a kit (human TIMP1 Quantikine ELISA; R&D
Systems). All patients enrolled in the present study gave
informed consent to participate. The study was approved by
the ethical board of the University Hospital of Heidelberg,
Germany.
Animal studies All animal studies were approved by the
veterinary office of Zürich. Male C57BL/6J mice were
kept on a 12/12 h light/dark cycle in a pathogen-free
animal facility. C57Bl/6J-Lepob mice were obtained from
Jackson Laboratory (Bar Harbor, ME, USA). For diet-
induced obesity, mice were fed a high-fat diet (Provimi
Kliba, Kaiseraugst, Switzerland) containing 60% energy
from fat. High-fat diet was given for 14 weeks (tissue
expression and secretion studies) or 8 weeks (TIMP1
serum concentrations). Control animals on a regular chow
diet were killed at the corresponding age. For murine
TIMP1 injection studies, subcutaneous murine TIMP1
(200 μg/kg) or PBS injections were administered daily
into the scapular region of male C57BL/6J mice (age 6–
8 weeks) for 3 weeks, during which mice were fed a high-
fat diet. For analysis of short-term effects, mice were
injected with murine TIMP1 and fed a high-fat diet for
three consecutive days, followed by metabolism cage
analysis of oxygen consumption (V

O2), carbon dioxide
production (V

CO2), food intake and physical activity
using a metabolism cage system (Oxymax; Columbus
Instruments, Columbus, OH, USA).
Serum measurements Blood glucose was measured with a
glycometer (Contour, Bayer HealthCare, Zürich, Switzer-
land). For the insulin tolerance test, insulin (0.75 U/kg of
body weight) was injected after 3 weeks of high-fat diet and
murine TIMP1 injections. Insulin was determined with a kit
(Rat/Mouse Insulin ELISA; Crystal Chem, Downers Grove,
IL, USA). Triacylglycerol and NEFAwere measured with the
following kits: Trig/GB (Roche/Hitachi, Basel, Switzerland);
and NEFA-HR kit (Wako, Neuss, Germany). TIMP1 serum
levels were assessed with a kit (Quantikine Mouse TIMP1
ELISA; R&D Systems).
Liver triacylglycerol Lipids from 150 mg liver were
extracted with 1 ml hexane:isopropanol (3:2) by homoge-
nising the tissue in a TissueLyser. Supernatant fraction was
taken off and the extraction repeated with 0.5 ml hexane/
isopropanol. We then added 0.5 ml 15% (wt/vol.) Na2SO4
and evaporated the upper organic phase overnight. Lipids
were dissolved in 2 ml Triton X-100/methanol/butanol
(1:1:3) and measured with the Trig/GB Kit (Roche/Hitachi,
Basel, Switzerland).
Adipocyte and fat pad size Adipose tissue was fixed
overnight in 5% (wt/vol.) paraformaldehyde before paraffin
embedding and sectioning to 10 μm slices. Haematoxylin and
eosin staining of sections was performed according to standard
procedures [32]. Microscopic pictures were taken and cell size
analysed using Cell Profiler Software [31]. Fat pads were
measured with an animal computed tomography scanner
(LaTheta; Echo Medical Systems, Houston, TX, USA).
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Ex vivo glucose uptake Ex vivo glucose uptake was
performed essentially as described previously [33]. After
a 6 h fast during the dark period, extensor digitorum
longus muscles and adipose tissue were dissected and
incubated for 20 min at 37°C in KRB buffer containing
0.1% (wt/vol.) BSA, 5 mmol/l HEPES and 10mmol/l glucose
with or without 10 nmol/l insulin. Tissues were rinsed
and glucose transport assessed during 75 min at 37°C using
2-deoxy[14C]glucose (0.07 MBq; Perkin Elmer, Schwerzen-
bach, Switzerland) in KRB with or without insulin. Tissues
were incubated for another 10 min at 37°C in KRB to
remove extracellular radiolabelled glucose. Tissues were
incubated overnight at −20°C in 1 mol/l NaOH. Samples
were dounced and centrifuged at 13,000 g for 10 min.
Radioactivity was determined by liquid scintillation counting
(Beckman Coulter, Brea, CA, USA) using a liquid scintil-
lation cocktail (Ultima Gold; Perkin Elmer).
Statistical analysis Results are given as mean ± standard
deviation. Statistical analyses were performed using a two-
tailed Student’s t test.
Results
It is known that obesity leads to a decreased capacity of
compensatory de novo adipogenesis [34, 35], which is
influenced by paracrine or endocrine factors. We
therefore analysed whether Timp1 mRNA expression
was deregulated in mouse models of obesity. In mice
with diet-induced obesity mRNA expression of Timp1 was
upregulated in several tissues, including liver, kidney,
heart, colon, thymus and brain. The most prominent
increase in Timp1 mRNA expression was seen in adipose
tissue (Fig. 1a). These data were corroborated against
TIMP1 protein levels in adipose tissue and heart muscle.
TIMP1 protein levels were increased two- to fourfold in
subcutaneous and visceral adipose tissue of obese com-
pared with lean mice, whereas TIMP1 protein in heart
muscle was only mildly affected. TIMP1 protein was
generally more abundant in visceral than in subcutaneous
adipose tissue compartments (Fig. 1b). As TIMP1 is a
circulating factor, we also measured TIMP1 in the serum
of lean and obese mice. In ob/ob mice and mice with diet-
induced obesity, TIMP1 serum concentrations were upre-
gulated three- to fourfold compared with lean mice
(Fig. 1c).
To get further insight into TIMP1 secretion from adipose
tissue, protein secretion was measured in different fat
depots and cell fractions. TIMP1 secretion was higher in
visceral than in subcutaneous adipose tissue (Fig. 1d).
TIMP1 secretion was also higher from SVF than from
adipocytes, though direct comparisons between adherent
SVF and adipocytes based on cellular protein content are
difficult. TIMP1 secretion of SVF from mice fed a high-fat
diet for 14 weeks did not differ compared with SVF from
lean mice. However, adipocytes from animals on high-fat
diet showed higher levels of TIMP1 secretion than those
from mice fed a standard chow diet (Fig. 1d).
As it has been reported that TIMP1 serum levels are
higher in obese than lean patients [26], we analysed
whether TIMP1 serum levels in participants with severe
obesity also correlated with type 2 diabetes. In an obese
cohort of 20 men (BMI 32.9–54.9 kg/m2), there was a
significant positive correlation between TIMP1 serum
levels and HOMA index, whereas BMI did not correlate
with circulating TIMP1 levels in these obese patients
(Fig. 1e, f). In female patients there was no significant
correlation (data not shown).
Whereas TIMP1 serum levels also increased in mice in
the context of obesity (Fig. 1c), TIMP1 serum levels in a
mouse model of type 1 diabetes (streptozotocin-induced)
did not differ compared with control mice. In summary,
these results indicate that the increase in TIMP1 serum
levels is predominantly associated with obesity.
To shed light on a possible role of TIMP1 in adipo-
genesis, we analysed Timp1 mRNA expression in the
course of 3T3-L1 adipocyte differentiation. Expression of
Timp1 mRNA dropped at the time of induction and was
very low in post-confluent differentiating 3T3-L1 pre-
adipocytes (Fig. 1g).
To test whether murine TIMP1 also plays a functional
role in adipogenesis, we purified recombinant mouse
TIMP1 (murine TIMP1) from the cell culture supernatant
fraction (Fig. 2a). As seen in Fig. 2b, c, increasing amounts
of murine TIMP1 added to the medium in the range of
endogenously secreted TIMP1 from 3T3-L1 pre-adipocytes
(1.27±0.14 μg/ml) led to a progressive decrease in 3T3-L1
adipocyte formation. We next tested whether this inhibitory
effect could also be seen in primary cells from murine
adipose SVF. Whereas addition of murine TIMP1 did not
change the differentiation capacity of visceral SVF, it did
lower the degree of differentiation in subcutaneous SVF
(Fig. 3a–c). The opposite effect was achieved using a
neutralising antibody against TIMP1, which increased
adipocyte differentiation in subcutaneous SVF only
(Fig. 3d,e).
Previous reports using the human analogue of TIMP1
(human TIMP1) in cell culture models of adipogenesis did
not observe any influence on adipocyte differentiation. As
human and mouse TIMP1 only share 72% homology, we
hypothesised that the human and murine isoforms of
TIMP1 inhibit MMPs to differing degrees. We therefore
compared the ability of human TIMP1 to inhibit murine
MMP9 or human MMP9 in an MMP activity assay. As
shown in Fig. 3f, human TIMP1 inhibited proteolytic
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Fig. 1 TIMP1 changes in obe-
sity. a Tissue mRNA expression
of Timp1 in male C57Bl/6J mice
on chow diet (black bars) or
after 14 weeks of high-fat diet
(white bars). Expression was
normalised to Rplp0; n=5.
b TIMP1 protein levels in tissue
extracts of subcutaneous fat,
visceral fat and heart muscle
from male C57Bl/6J mice on
chow diet (black bars) or high-
fat diet (grey bars) or crossed
into the ob/ob background
(white bars). TIMP1 protein
concentration was measured by
ELISA and normalised to total
protein concentration; n=4.
c TIMP1 protein concentrations
in serum of lean and obese mice
measured by ELISA; n=5.
d TIMP1 protein secretion from
murine SVF or adipocytes of
C57Bl/6J mice on chow diet
(black bars) or high-fat diet
(grey bars). Supernatant frac-
tions were collected after 24 h
and TIMP1 concentrations mea-
sured by ELISA; n=5. e Human
TIMP1 serum concentrations in
obese men plotted against
HOMA index or (f) BMI; n=20.
e R2=0.34, p=0.009;
(f) R2=0.00, p=0.96.
g mRNA expression of Timp1
(inverted triangles), Pparγ
(triangles) and A-Fabp (squares)
normalised to Rplp0 in the course
of 3T3-L1 differentiation; n=5.
Values represent mean ± SD;
*p<0.05, **p<0.01,
***p<0.001
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activity of human MMP9 more efficiently than that of
murine MMP9. In addition, we analysed the efficacy of
human and murine TIMP1 to inhibit murine MMP9
activity. As seen in Fig. 3g, murine TIMP1 showed a
higher inhibition of murine MMP9 than of human TIMP1.
To analyse whether murine TIMP1 also affected adipo-
cyte plasticity in vivo we treated male C57BL/6J mice fed a
high-fat diet with murine TIMP1. Treatment involved daily
injection of 200 μg/kg body weight of murine TIMP1 or
PBS into subcutaneous, scalpular adipose tissue for a time
period of 3 weeks. Apart from local accumulation in the
subcutaneous fat, this injection regime also led to increased
circulating blood levels of TIMP1 approximately threefold
over baseline levels (Fig. 4a). To assess the effect of murine
TIMP1 injection on adipose tissue development, we
measured whole body weight as well as fat pad weight by
computed tomography scanning (Fig. 4b, c). Body and fat
pad weight gain did not differ between PBS-injected and
murine TIMP1-injected mice. However, we did observe an
increase in mean adipocyte size and a shift in the size
distribution towards larger adipocytes in mice injected with
murine TIMP1 (Fig. 4d–f). This is in line with the
observation that murine TIMP1 inhibits adipocyte forma-
tion, thus causing adipocyte hypertrophy.
Moreover, mice injected with murine TIMP1 showed
higher blood glucose and insulin levels, as well as
decreased insulin sensitivity in an insulin tolerance test
compared with control animals, indicating increased insulin
resistance (Fig. 5a–c). In line with this, NEFA serum
concentrations and liver triacylglycerol content were in-
creased in mice treated with murine TIMP1 (Fig. 5d,e),
whereas serum triacylglycerol levels were unchanged
(Fig. 5f). To analyse whether murine TIMP1 injections
altered glucose uptake specifically in adipose tissue, we
perfomed ex vivo glucose uptake studies in fat and muscle
from mice that had been injected with murine TIMP1 or
PBS for 3 weeks in combination with a high-fat diet. As
seen in Fig. 5g, murine TIMP1 injections led to decreased
insulin-stimulated glucose uptake predominantly into sub-
cutaneous and, to a minor extent, into visceral adipose
tissue, whereas muscle glucose uptake was unaffected.
To elucidate whether murine TIMP1 injections influ-
enced MMP levels in adipose tissue, we analysed produc-
tion of MMP2 and MMP9, which are known to inhibit
adipogenesis [36]. Although MMP levels varied between
mice, we saw a general trend towards upregulation of
MMP, with higher production of the inactive pro-form of
MMP9 and MMP2 in mice injected with murine TIMP1
(Fig. 6a–f). These data were corroborated against MMP
activity in adipose tissue extracts. As seen in Fig. 6g,
murine TIMP1 injections led to a significant decrease in
global MMP activity in subcutaneous as well as visceral
adipose tissue. Interestingly, global MMP activity as such
was considerably lower in visceral than in subcutaneous
adipose tissue.
Since it has been reported that some of the observed
effects of TIMP1 might be due to a central regulation of
energy balance, we tested respiration as well as activity of
ba
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the mice in a metabolism cage system after short-term
injections of murine TIMP1 (3 days) and after 3 weeks of
murine TIMP1 treatment. Neither short- (data not shown)
nor long-term (Fig. 7) murine TIMP1 injections led to
alterations in oxygen consumption, feeding or physical
activity, implying that murine TIMP1 injections do not
affect regulatory mechanisms of energy homeostasis in the
central nervous system.
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In summary, we show here that TIMP1 abundance is
upregulated in obesity. TIMP1 inhibits adipocyte differen-
tiation and leads to enlarged adipocytes in vivo. Mice
injected with murine TIMP1 mice show impaired NEFA
and glucose profiles, increased hepatic triacylglycerol
accumulation and faster development of insulin resistance.
Discussion
Tight regulation of extracellular matrix remodelling by
MMPs and their inhibitors such as TIMP1 is crucial for the
adipogenic process. The fact that TIMP1 is upregulated in
obesity partly due to increased abundance in adipose tissue
led to the assumption that TIMP1 influences adipose tissue
plasticity in the state of overnutrition.
We confirm here that TIMP1 is highly abundant in the
SVF of adipose tissue and that levels are higher in visceral
than in subcutaneous adipose tissue [18, 26, 37–39]. In
obese animals, TIMP1 secretion from mature adipocytes
was increased in all fat depots, whereas TIMP1 secretion
from SVF was not altered. These data conflict to some
extent with a report from Maury et al. [39], which shows
that TIMP1 secretion is higher from SVF and adipocytes in
human omental adipose tissue of obese patients compared
with lean participants. These differences might be due to
species differences or due to different culture and prepara-
tion conditions. Based on our observations, it can be
assumed that the increase of circulating TIMP1 levels in
obesity observed here and by others [26] is at least partly
due to increased secretion from mature adipocytes, as
TIMP1 levels in other TIMP1-producing tissues are
increased to a much lower extent.
As reported previously, TIMP1 production was
blunted at induction of adipocyte differentiation, hinting
at an inhibitory role of TIMP1 in adipogenesis [18]. We
g
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showed here that murine recombinant TIMP1 repressed
adipogenesis in 3T3-L1 pre-adipocytes and in subcutane-
ous SVF, whereas neutralisation of TIMP1 led to enhanced
differentiation. As TIMP1 inhibits a broad spectrum of
MMPs, these results are consistent with the fact that global
MMP inhibitors repress adipocyte differentiation in vitro
[18, 36]. In a previous study, Demeulemeester et al. [29]
reported that overabundant human TIMP1 had no effect
on adipocyte differentiation in 3T3-F332A pre-
adipocytes, whereas Alexander et al. [22] reported
enhanced adipogenesis using the MMP inhibitor
GM6001 or human TIMP1. The differences between
the various reports suggest that the balance between
inhibition of different classes of MMPs plays a crucial
role. In fact, different classes of MMPs are known to
have opposite effects on adipogenesis. Whereas MMP9
and MMP2 are reported to promote adipocyte formation
[36, 40, 41], MMP3 or MMP11 inhibit the latter [22, 42].
Additionally, TIMP1 can have MMP-independent effects
on cell growth [43]. One future challenge will therefore be
to study the ‘mechanics’ of how TIMP1 influences
adipogenesis.
In contrast to subcutaneous SVF, no effect of murine
TIMP1 or TIMP1 neutralisation could be seen in visceral
SVF. It is known that subcutaneous and visceral adipose
tissue show distinct gene expression patterns and that
visceral fat is a higher risk factor for insulin resistance
[11, 44]. As the differentiation capacity of visceral SVF as
such was seen here and elsewhere [45] to be much lower, it
is likely that other inhibitory factors apart from TIMP1
additionally control adipogenesis in visceral fat.
In vivo, global knockout of Timp1 leads to sex-specific
effects in mice with diet-induced obesity, giving rise to less
fat and smaller adipocytes in male animals, whereas female
mice with a null mutation develop bigger fat pads and
larger adipocytes [27, 28]. One issue is the impact of Timp1
ablation on the central nervous system, leading to hyper-
phagia in female mice, which might mask direct effects on
adipose tissue development. Male Timp1 knockout mice do
not show altered energy balance, but do display lower body
weights as early as at weaning, implying a role for TIMP1
in development. We did not observe any changes in energy
balance in murine TIMP1-injected mice, nor did murine
TIMP1 injections influence fat pad growth during high-fat
diet feeding. This suggests that the observed increase in
adipocyte size goes in hand with a decrease in adipocyte
number, which is possibly a result of decreased compensa-
tory adipogenesis in mice injected with murine TIMP1.
Demeulemeester et al. reported that chronic overabun-
dance of human TIMP1 had no effect on adipose tissue
development [29], whereas Alexander et al. observed more,
hypertrophied adipocytes in the mammary gland [22]. Here,
we were able to show that injection of murine TIMP1 into
subcutaneous fat during 3 weeks of high-fat diet led to
enlarged adipocytes in subcutaneous fat pads. Discrepan-
cies can be partially attributed to species-specific differ-
ences, as human TIMP1 is less efficient in inhibiting
murine MMP9 than human MMP9. Furthermore, human
TIMP1 is also less efficient than murine TIMP1 in
regulating murine MMP9 activity. In addition, overabun-
dance in the liver [29] might also change activity of human
TMP1 by alternate mechanisms.
Murine TIMP1 injections under a high-fat diet also led
to an impaired metabolic profile. It is known that enlarged
adipocytes become insulin-resistant and have a high
lipolytic rate [8, 9, 46, 47]. As murine TIMP1 injections
did not alter muscle glucose uptake, it can be excluded that
altered muscle function contributed to the observed changes
in glucose metabolism. Although it cannot be ruled out that
TIMP1 acts on other metabolic tissues, the elevated serum
levels of NEFA seen here hint at a contribution of disturbed
adipose tissue function to this phenotype. Elevated NEFA
levels in turn cause increased hepatic triacylglycerol
accumulation, promoting insulin resistance [4]. Interesting-
ly, a positive correlation was also found between circulating
TIMP1 levels and insulin resistance in our group of obese
men. This correlation supports the link between TIMP1
levels and insulin resistance.
Murine TIMP1 injections led to decreased MMP activity
in adipose tissue, suggesting that the observed metabolic
effects are at least partly due to altered adipose tissue MMP
activity. Interestingly, MMP activity in visceral vs subcu-
taneous adipose tissue was much lower in itself, a finding
that is consistent with the increased endogenous levels of
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TIMP1 in visceral fat. Given the fact that murine TIMP1
inhibited adipogenesis and increased adipocyte size, espe-
cially in subcutaneous adipose tissue where endogenous
TIMP1 levels are low, it can be speculated that TIMP1
injections increase subcutaneous adipose tissue insulin
resistance under high-fat diet feeding, a process that is
normally seen predominantly in visceral adipose tissue.
This is supported by the fact that insulin-stimulated glucose
uptake was lower in visceral than in subcutaneous adipose
tissue in control animals and much less affected by TIMP1
treatment.
It is well known that proinflammatory cytokines and
adipokines are upregulated in adipose tissue of obese
participants and contribute to insulin resistance [48, 49].
In 3T3-L1 adipocytes, TIMP1 can be induced by cytokines
such as TNFα, IL-6 and IL1-β [50, 51]. It is therefore
intriguing to speculate that increased TIMP1 production in
obesity is driven by inflammatory signals, thus inhibiting
differentiation of new adipocytes. In fact, it has been shown
that the differentiation capacity of SVF from obese mice is
impaired, which could in turn lead to adipocyte hypertro-
phy and increased insulin resistance [52].
Based on these findings, TIMP1 might serve as a target
for modulation of adipose tissue plasticity in response to
adiposity. Inhibition of TIMP1 would result in an improved
hyperplastic response of adipose tissue, which is known to
reduce the risk of insulin resistance.
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